

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 Jun 2026

Comparing the effectiveness of topiramate treatment with haloperidol in chronic tic disorder

Protocol summary

Study aim

treatment of chronic tic disorder

Design

A clinical trial with two parallel intervention groups, without blinding, randomized, phase 2 on 32 patients. A table of random numbers was used for randomization.

Settings and conduct

This study will be conducted in 1402 in the city of Isfahan in the population of children with chronic tic disorder. The participants will be placed in one of the two treatment groups of topiramate or haloperidol. Blinding will not be done in this study.

Participants/Inclusion and exclusion criteria

This study is conducted on children aged 6 to 12 years who have the informed consent of their parents to participate in the study and do not have any other psychiatric disorder or history of any other disease.

Intervention groups

Children in this study are treated in two groups. The first group was treated with haloperidol at a dose of 0.225 to 8 mg per day and the second group was treated with topiramate at a dose of 50 to 200 mg per day.

Main outcome variables

tic

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230803059021N1**

Registration date: **2023-08-10, 1402/05/19**

Registration timing: **prospective**

Last update: **2023-08-10, 1402/05/19**

Update count: **0**

Registration date

2023-08-10, 1402/05/19

Registrant information

Name

Fahime Rezaie

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 913 328 9507

Email address

rezaeedr022@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-08-23, 1402/06/01

Expected recruitment end date

2023-09-23, 1402/07/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparing the effectiveness of topiramate treatment with haloperidol in chronic tic disorder

Public title

topiramate treatment with haloperidol in chronic tic disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

parental informed consent DSM-V criteria for chronic tic disorder age between 6 and 12

Exclusion criteria:

Presence of major medical disorders such as epilepsy, diabetes, heart and kidney diseases mental retardation

Hypersensitivity to topiramate and haloperidol The presence of concomitant psychiatric disorders that require drug intervention History of long QT syndrome, cardiac arrhythmia, kidney stones and concurrent use of carbonic anhydrase inhibitor drugs

Age

From **6 years** old to **12 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: **32**

Randomization (investigator's opinion)

Randomized

Randomization description

First, with the help of a random number table, a number of random numbers were generated according to the sample size, and then they were placed in sealed envelopes in this order and numbered on the envelopes. Then, according to the order in which the participants entered the study, an envelope is opened and a random sequence is determined.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Isfahan University of Medical Sciences

Street address

Hezar Jarib

City

Isfahan

Province

Isfahan

Postal code

8974673461

Approval date

2023-04-29, 1402/02/09

Ethics committee reference number

IR.MuI.MED.REC.1402.059

Health conditions studied**1****Description of health condition studied**

chronic tic disorder

ICD-10 code

F95.1

ICD-10 code description

Chronic motor or vocal tic disorder

Primary outcomes**1****Description**

tic

Timepoint

before treatment and 1 month after and 2 month after

Method of measurement

Yale Global Tic Severity scale

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: Treatment with haloperidol manufactured by Subhan Daru company in the form of 0.25 to 8 mg daily for 2 months

Category

Treatment - Drugs

2**Description**

Intervention group: Treatment with topiramate drug manufactured by Elixir Danesh company in the form of 50 to 200 mg daily for 2 months

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Amin hospital

Full name of responsible person

Fahime Rezaie

Street address

Hezar Jarib

City

Isfahan

Province

Isfahan

Postal code

8974673461

Phone

+98 913 328 9507

Email

rezaeedr022@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Gholamreza Asgari

Street address

Hezar Jarib

City

Isfahan

Province

Isfahan

Postal code

8974673461

Phone

+98 31 3668 8138

Email

askari@mui.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Faime Rezaie

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Psychiatrics

Street address

Hezar Jarib

City

Isfahan

Province

Isfahan

Postal code

8974673461

Phone

+98 31 3668 8138

Email

rezaeedr022@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Fahime Rezaie

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Psychiatrics

Street address

Hezar Jarib

City

Isfahan

Province

Isfahan

Postal code

8974673461

Phone

+98 31 3668 8138

Email

rezaeedr022@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Fahime Rezaie

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Psychiatrics

Street address

Hezar Jarib

City

Isfahan

Province

Isfahan

Postal code

8974673461

Phone

+98 31 3668 8138

Email

rezaeedr022@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

no more information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available